Macarena Hernández-Jiménez, PhD; Francisco Abad-Santos, MD; Ian Cotgreave, PhD; et al.
free access
JAMA Neurol. 2023;80(8):779-788. doi:10.1001/jamaneurol.2023.1660
This randomized clinical trial investigates the safety and efficacy of ApTOLL as a neuroprotectant drug for patients with ischemic stroke when given in combination with endovascular treatment.
Izanne Roos, MBChB, PhD; Stella Hughes, MD; Gavin McDonnell, MD, PhD; et al.
free access
JAMA Neurol. 2023;80(8):789-797. doi:10.1001/jamaneurol.2023.1625
This cohort study investigates if rituximab is noninferior to ocrelizumab in the prevention of relapses and disability in patients with relapsing-remitting multiple sclerosis.
Michael Strupp, MD; Marco Mandala, MD, PhD; Anne-Sophie Vinck, MD; et al.
free access
has multimedia
JAMA Neurol. 2023;80(8):798-804. doi:10.1001/jamaneurol.2023.1408
This randomized clinical trial compares the efficacy of the Semont-plus maneuver and the Epley maneuver in patients with posterior canal benign paroxysmal positional vertigo.
-
Video:
Demonstration of the Semont-Plus Self-maneuver for Right Posterior Canal Canalithiasis
-
Video:
Semont-Plus Maneuver for Right Posterior Canal Benign Paroxysmal Positional Vertigo
-
Video:
Demonstration of the Epley Self-maneuver for a Right Posterior Canal Canalithiasis
Jesper Tveit, PhD; Harald Aurlien, MD, PhD; Sergey Plis, PhD; et al.
open access
has audio
JAMA Neurol. 2023;80(8):805-812. doi:10.1001/jamaneurol.2023.1645
This diagnostic study investigates whether an artificial intelligence model can be trained to interpret clinical encephalograms similar to human experts.
-
Podcast:
Automated Interpretation of Clinical Electroencephalograms Using Artificial Intelligence
Emile d鈥橝ngremont, MSc; Marieke J. H. Begemann, PhD; Teus van Laar, MD, PhD; et al.
free access
JAMA Neurol. 2023;80(8):813-823. doi:10.1001/jamaneurol.2023.1835
This meta-analysis examines the use of cholinesterase inhibitors as treatment of psychotic symptoms in patients with Alzheimer disease, Parkinson disease, and dementia with Lewy bodies.
Fouzi Bala, MD; Nishita Singh, MD; Brian Buck, MD; et al.
free access
JAMA Neurol. 2023;80(8):824-832. doi:10.1001/jamaneurol.2023.2094
This prespecified secondary analysis of the ACT randomized clinical trial evaluates the safety and efficacy of tenecteplase compared to alteplase among patients with large vessel occlusion stroke.
Stefan Wolf, MD; Dorothee Mielke, MD; Christoph Barner, MD; et al.
open access
JAMA Neurol. 2023;80(8):833-842. doi:10.1001/jamaneurol.2023.1792
This pragmatic randomized clinical trial evaluates the effectiveness of early lumbar cerebrospinal fluid drainage added to standard of care in patients after aneurysmal subarachnoid hemorrhage.
Colin B. Josephson, MD, MSc; Arturo Gonzalez-Izquierdo, PhD; Spiros Denaxas, PhD; et al.
free access
JAMA Neurol. 2023;80(8):843-850. doi:10.1001/jamaneurol.2023.1580
This cohort study uses population-based data to quantify and model the independent hazards for osteoporosis associated with epilepsy and antiseizure medications.
Anxin Wang, PhD; Baixue Jia, MD; Xuelei Zhang, MD; et al.
free access
JAMA Neurol. 2023;80(8):851-859. doi:10.1001/jamaneurol.2023.1871
This randomized clinical trial assesses the efficacy and safety of DL-3-n-butylphthalide in patients with acute ischemic stroke receiving reperfusion therapy of intravenous thrombolysis and/or endovascular treatment.
Mackenzie Henderson, PharmD, MS; Daniel B. Horton, MD, MSCE; Vikram Bhise, MD; et al.
free access
JAMA Neurol. 2023;80(8):860-867. doi:10.1001/jamaneurol.2023.2125
This study evaluates patterns in disease-modifying therapy initiations between 2001 and 2020 among commercially insured US adults and children with multiple sclerosis.